A new generation of potent complement inhibitors of the compstatin family

Chemical Biology and Drug Design

Volumn 77, Issue 6, 2011, Pages 431-440

  López de Victoria, Aliana ^a   Gorham, Ronald D ^a   Bellows Peterson, Meghan L ^b   Ling, Jun ^c   Lo, David D ^c   Floudas, Christodoulos A ^b   Morikis, Dimitrios ^a  

^a University of California Riverside   (United States)

^b Princeton University   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complement system; Complement system inhibitors; Compstatin family; Peptide design; Structure based drug design

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPSTATIN; COMPSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; COMPLEMENT FIXATION; DRUG DESIGN; HUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT C3; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PEPTIDES, CYCLIC; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

EID: 79955950806     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01111.x     Document Type: Article

References (32)

1. Walport M.J. (2001) Advances in immunology: complement (first of two parts). N Engl J Med;344:1058-1066.
2. Walport M.J. (2001) Advances in immunology: complement (second of two parts). N Engl J Med;344:1140-1144.
3. Morikis D., Lambris J.D. (2005) Structure, dynamics, activity, and function of compstatin and design of more potent analogs. In: Morikis D., Lambris J.D., editors. Structural Biology of the Complement System. Boca Raton, FL: CRC Press/Taylor & Francis Group; p. 317-340.
4. Mollnes T.E., Kirschfink M. (2006) Strategies of therapeutic complement inhibition. Mol Immunol;43:107-121.
5. Morgan B.P., Harris C.L. (2003) Complement therapeutics; history and current progress. Mol Immunol;40:159-170.
6. Sahu A., Lambris J.D. (2000) Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology;49:133-148.
7. Sahu A., Kay B.K., Lambris J.D. (1996) Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol;157:884-891.
8. Morikis D., Lambris J.D. (2002) Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans;30:1026-1036.
9. Morikis D., Soulika A.M., Mallik B., Klepeis J.L., Floudas C.A., Lambris J.D. (2004) Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochem Soc Trans;32:28-32.
10. Holland M.C.H., Morikis D., Lambris J.D. (2004) Synthetic small molecule complement inhibitors. Curr Opin Investig Drugs;5:1164-1173.
11. Floudas C.A., Klepeis J.L., Lambris J.D., Morikis D. (2004) De novo protein design: an interplay of global optimization, mixed-integer optimization and experiments. In: Floudas C.A., Agrawal R., editors. FOCAPD 2004, Sixth International Conference on Foundations of Computer-Aided Process Design, Discovery through Product and Process Design. Austin, TX: CACHE Corporation; p. 133-146.
12. Morikis D., Floudas C.A., Lambris J.D. (2005) Structure-based integrative computational and experimental approach for the optimization of drug design. In: Sunderam V.S., van Albada G.D., Sloot P.M.A., Dongarra J.J., editors. ICCS 2005, Lecture Notes in Computer Science: Computational Science. Berlin-Heidelberg: Springer-Verlag; p. 680-688.
13. Ricklin D., Lambris J.D. (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol;632:273-292.
14. Morikis D., Assa-Munt N., Sahu A., Lambris J.D. (1998) Solution structure of compstatin, a potent complement inhibitor. Protein Sci;7:619-627.
15. Morikis D., Roy M., Sahu A., Troganis A., Jennings P.A., Tsokos G.C., Lambris J.D. (2002) The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR. J Biol Chem;277:14942-14953.
16. Klepeis J.L., Floudas C.A., Morikis D., Tsokos C.G., Argyropoulos E., Spruce L., Lambris J.D. (2003) Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J Am Chem Soc;125:8422-8423.
17. Mallik B., Katragadda M., Spruce L.A., Carafides C., Tsokos C.G., Morikis D., Lambris J.D. (2005) Design and NMR characterization of active analogs of compstatin containing non-natural amino acids. J Med Chem;48:274-286.
18. Mallik B., Lambris J.D., Morikis D. (2003) Conformational inter-conversion of compstatin probed with molecular dynamics simulations. Proteins;53:130-141.
19. Mallik B., Morikis D. (2005) Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogs. J Am Chem Soc;127:10967-10976.
20. Katragadda M., Magotti P., Sfyroera G., Lambris J.D. (2006) Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor compstatin. J Med Chem;49:4616-4622.
21. Janssen B.J.C., Halff E.F., Lambris J.D., Gros P. (2007) Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem;282:29241-29247.
22. Bellows M.L., Fung H.K., Taylor M.S., Floudas C.A., López De Victoria A., Morikis D. (2010) New compstatin variants through two de novo protein design frameworks. Biophys J;98:2337-2346.
23. Sahu A., Soulika A., Morikis D., Spruce L., Moore W.T., Lambris J.D. (2000) Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor Compstatin. J Immunol;165:2491-2499.
24. Sahu A., Morikis D., Lambris J.D. (2003) Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol;39:557-566.
25. Soulika A.M., Morikis D., Sarrias M.-R., Roy M., Spruce L.A., Sahu A., Lambris J.D. (2003) Studies of structure-activity relations of complement inhibitor compstatin. J Immunol;170:1881-1890. Erratum: 2004, 172-5128.
26. Ling J., Liao H., Clark R., Wong M.S., Lo D.D. (2008) Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem;283:30585-30595.
27. Karlsson R., Fält A. (1997) Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods;200:121-133.
28. Lilien R.H., Stevens B.W., Anderson A.C., Donald B.R. (2005) A novel ensemble-based scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the Gramicidin Synthetase A Phenylalanine Adenylation enzyme. J Comp Biol;12:740-761.
29. Katragadda M., Morikis D., Lambris J.D. (2004) Thermodynamic studies on the interaction of the third complement component and its inhibitor compstatin. J Biol Chem;279:54987-54995.
30. Magotti P., Ricklin D., Qu H., Wu Y.-Q., Kaznessis Y.N., Lambris J.D. (2009) Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit;22:495-505.
31. Klepeis J.L., Floudas C.A., Morikis D., Tsokos C.G., Lambris J.D. (2004) Design of peptide analogs with improved activity using a novel de novo protein design approach. Ind Eng Chem Res;43:3817-3826.
32. Tamamis P., Morikis D., Floudas C.A., Archontis G. (2010) Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations. Proteins;78:2655-2667.